References
1. de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: From
Biology to Clinical Management. J Clin Med . Jan 9
2015;4(1):127-49. doi:10.3390/jcm4010127
2. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and
management of acute myeloid leukemia in children and adolescents:
recommendations from an international expert panel. Blood . Oct 18
2012;120(16):3187-205. doi:10.1182/blood-2012-03-362608
3. Shallis RM, Gale RP, Lazarus HM, et al. Myeloid sarcoma, chloroma, or
extramedullary acute myeloid leukemia tumor: A tale of misnomers,
controversy and the unresolved. Blood Rev . May 2021;47:100773.
doi:10.1016/j.blre.2020.100773
4. Zorn KE, Cunningham AM, Meyer AE, Carlson KS, Rao S. Pediatric
Myeloid Sarcoma, More than Just a Chloroma: A Review of Clinical
Presentations, Significance, and Biology. Cancers (Basel) . Feb 24
2023;15(5)doi:10.3390/cancers15051443
5. Eckardt JN, Stolzel F, Kunadt D, et al. Molecular profiling and
clinical implications of patients with acute myeloid leukemia and
extramedullary manifestations. J Hematol Oncol . May 13
2022;15(1):60. doi:10.1186/s13045-022-01267-7
6. Liu PI, Ishimaru T, McGregor DH, Okada H, Steer A. Autopsy study of
granulocytic sarcoma (chloroma) in patients with myelogenous leukemia,
Hiroshima-Nagasaki 1949-1969. Cancer . Apr 1973;31(4):948-55.
doi:10.1002/1097-0142(197304)31:4<948::aid-cncr2820310428>3.0.co;2-n
7. Hazar V, Ozturk G, Yalcin K, et al. Different Kinetics and Risk
Factors for Isolated Extramedullary Relapse after Allogeneic
Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia.Transplant Cell Ther . Oct 2021;27(10):859 e1-859 e10.
doi:10.1016/j.jtct.2021.06.023
8. Hicsonmez G, Cetin M, Tuncer AM, et al. Children with acute
myeloblastic leukemia presenting with extramedullary infiltration: the
effects of high-dose steroid treatment. Leuk Res . Jan
2004;28(1):25-34. doi:10.1016/s0145-2126(03)00159-0
9. Bisschop MM, Revesz T, Bierings M, et al. Extramedullary infiltrates
at diagnosis have no prognostic significance in children with acute
myeloid leukaemia. Leukemia . Jan 2001;15(1):46-9.
doi:10.1038/sj.leu.2401971
10. Kobayashi R, Tawa A, Hanada R, et al. Extramedullary infiltration at
diagnosis and prognosis in children with acute myelogenous leukemia.Pediatr Blood Cancer . Apr 2007;48(4):393-8. doi:10.1002/pbc.20824
11. Stove HK, Sandahl JD, Abrahamsson J, et al. Extramedullary leukemia
in children with acute myeloid leukemia: A population-based cohort study
from the Nordic Society of Pediatric Hematology and Oncology (NOPHO).Pediatr Blood Cancer . Dec 2017;64(12)doi:10.1002/pbc.26520
12. Dusenbery KE, Howells WB, Arthur DC, et al. Extramedullary leukemia
in children with newly diagnosed acute myeloid leukemia: a report from
the Children’s Cancer Group. J Pediatr Hematol Oncol . Oct
2003;25(10):760-8. doi:10.1097/00043426-200310000-00004
13. Schwyzer R, Sherman GG, Cohn RJ, Poole JE, Willem P. Granulocytic
sarcoma in children with acute myeloblastic leukemia and t(8;21).Med Pediatr Oncol . Sep 1998;31(3):144-9.
doi:10.1002/(sici)1096-911x(199809)31:3<144::aid-mpo3>3.0.co;2-b
14. Xin X, Zhu H, Chang Z, et al. Risk factors and prognosis analysis of
acute myeloid leukemia in children. J BUON . Jan-Feb
2021;26(1):166-172.
15. Lee JW, Kim S, Jang PS, et al. Prognostic Role of Postinduction
Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary
Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.J Pediatr Hematol Oncol . Apr 2020;42(3):e132-e139.
doi:10.1097/MPH.0000000000001623
16. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Superior
outcome of pediatric acute myeloid leukemia patients with orbital and
CNS myeloid sarcoma: a report from the Children’s Oncology Group.Pediatr Blood Cancer . Apr 2012;58(4):519-24.
doi:10.1002/pbc.23201
17. Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in
children and adolescents with de novo acute myeloid leukemia improves
event-free survival by reducing relapse risk: results from the
randomized phase III Children’s Oncology Group trial AAML0531. J
Clin Oncol . Sep 20 2014;32(27):3021-32. doi:10.1200/JCO.2014.55.3628
18. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of
the safety of gemtuzumab ozogamicin in combination with chemotherapy for
newly diagnosed childhood acute myeloid leukemia: a report from the
Children’s Oncology Group. Cancer . Feb 1 2012;118(3):761-9.
doi:10.1002/cncr.26190
19. Kim EH, Im SA, Lee JW, Kim S, Cho B. Extramedullary Infiltration in
Pediatric Acute Myeloid Leukemia on Surveillance Magnetic Resonance
Imaging and its Relationship With Established Risk Factors. J
Pediatr Hematol Oncol . Apr 1 2022;44(3):e713-e718.
doi:10.1097/MPH.0000000000002353
20. Stolzel F, Luer T, Lock S, et al. The prevalence of extramedullary
acute myeloid leukemia detected by (18)FDG-PET/CT: final results from
the prospective PETAML trial. Haematologica . Jun
2020;105(6):1552-1558. doi:10.3324/haematol.2019.223032
21. Cribe AS, Steenhof M, Marcher CW, Petersen H, Frederiksen H, Friis
LS. Extramedullary disease in patients with acute myeloid leukemia
assessed by 18F-FDG PET. Eur J Haematol . Apr 2013;90(4):273-8.
doi:10.1111/ejh.12085
22. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. The presence
of central nervous system disease at diagnosis in pediatric acute
myeloid leukemia does not affect survival: a Children’s Oncology Group
study. Pediatr Blood Cancer . Sep 2010;55(3):414-20.
doi:10.1002/pbc.22511
23. Pramanik R, Tyagi A, Chopra A, Kumar A, Vishnubhatla S, Bakhshi S.
Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can
Cytogenetics Solve the Puzzle? Clin Lymphoma Myeloma Leuk . Jun
2018;18(6):e249-e254. doi:10.1016/j.clml.2018.03.013
24. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Risk factors
and therapy for isolated central nervous system relapse of pediatric
acute myeloid leukemia. J Clin Oncol . Dec 20 2005;23(36):9172-8.
doi:10.1200/JCO.2005.02.7482
25. Hu GH, Lu AD, Jia YP, Zuo YX, Wu J, Zhang LP. Prognostic Impact of
Extramedullary Infiltration in Pediatric Low-risk Acute Myeloid
Leukemia: A Retrospective Single-center Study Over 10 Years. Clin
Lymphoma Myeloma Leuk . Nov 2020;20(11):e813-e820.
doi:10.1016/j.clml.2020.06.009
26. Yoshihara S, Ando T, Ogawa H. Extramedullary relapse of acute
myeloid leukemia after allogeneic hematopoietic stem cell
transplantation: an easily overlooked but significant pattern of
relapse. Biol Blood Marrow Transplant . Dec 2012;18(12):1800-7.
doi:10.1016/j.bbmt.2012.05.010
27. Harris AC, Kitko CL, Couriel DR, et al. Extramedullary relapse of
acute myeloid leukemia following allogeneic hematopoietic stem cell
transplantation: incidence, risk factors and outcomes.Haematologica . Feb 2013;98(2):179-84.
doi:10.3324/haematol.2012.073189
28. Shem-Tov N, Saraceni F, Danylesko I, et al. Isolated Extramedullary
Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation:
Different Kinetics and Better Prognosis than Systemic Relapse.Biol Blood Marrow Transplant . Jul 2017;23(7):1087-1094.
doi:10.1016/j.bbmt.2017.03.023
29. Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation
for paediatric AML in first remission: a systematic review and
meta-analysis. Bone Marrow Transplant . May 2002;29(10):843-52.
doi:10.1038/sj.bmt.1703528
30. Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on
biology, risk stratification, and therapy. Curr Opin Pediatr . Feb
2020;32(1):57-66. doi:10.1097/MOP.0000000000000855
31. Chevallier P, Mohty M, Lioure B, et al. Allogeneic hematopoietic
stem-cell transplantation for myeloid sarcoma: a retrospective study
from the SFGM-TC. J Clin Oncol . Oct 20 2008;26(30):4940-3.
doi:10.1200/JCO.2007.15.6315
32. Xu LH, Wang Y, Chen ZY, Fang JP. Myeloid sarcoma is associated with
poor clinical outcome in pediatric patients with acute myeloid leukemia.J Cancer Res Clin Oncol . Apr 2020;146(4):1011-1020.
doi:10.1007/s00432-020-03128-7
33. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab
ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res .
Jun 2001;7(6):1490-6.
34. Kharfan-Dabaja MA, Hamadani M, Reljic T, et al. Gemtuzumab
ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a
systematic review and meta-analysis. Br J Haematol . Nov
2013;163(3):315-25. doi:10.1111/bjh.12528
35. Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A. Gemtuzumab
therapy for isolated extramedullary AML relapse following allogeneic
stem-cell transplant. Nat Clin Pract Oncol . Aug 2007;4(8):491-5.
doi:10.1038/ncponc0899
36. Sangle NA, Schmidt RL, Patel JL, et al. Optimized
immunohistochemical panel to differentiate myeloid sarcoma from blastic
plasmacytoid dendritic cell neoplasm. Mod Pathol . Aug
2014;27(8):1137-43. doi:10.1038/modpathol.2013.238
37. Kaur V, Swami A, Alapat D, et al. Clinical characteristics,
molecular profile and outcomes of myeloid sarcoma: a single institution
experience over 13 years. Hematology . Jan 2018;23(1):17-24.
doi:10.1080/10245332.2017.1333275